SAT-690 - Risk of Ileus in Hospitalized Patients with Obesity Receiving GLP-1 Receptor Agonists

Risk of Ileus in Hospitalized Patients With Obesity Receiving GLP-1 Receptor Agonists

Introduction:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the management of type 2 diabetes mellitus and obesity. Although generally well tolerated, these agents commonly affect gastrointestinal motility, raising concern for potential complications such as ileus. Evidence regarding the prevalence of ileus among hospitalized patients treated with GLP-1 RAs remains limited. This study aimed to evaluate the prevalence of ileus in hospitalized patients receiving GLP-1 RAs and to identify associated clinical factors.

Methods:
We conducted a retrospective cohort study with propensity score matching (PSM) using the TriNetX global federated real-world data network. Hospitalized adults with a body mass index (BMI) ≥ 30 who had received semaglutide, liraglutide, or tirzepatide prior to admission were identified and compared with hospitalized patients without prior GLP-1 RA exposure. One-to-one PSM was performed to balance demographic characteristics, medication exposures, and relevant clinical risk factors. The primary outcome was the prevalence of ileus during hospitalization. Risk estimates were reported as hazard ratios (HR) with 95% confidence intervals (CI), and statistical significance was defined as a two-sided p-value < 0.05.

Results:
A total of 79,436 hospitalized patients receiving GLP-1 RAs and 79,346 hospitalized patients without GLP-1 RA exposure were identified. Ileus occurred in 229 patients (0.29%) in the GLP-1 RA cohort and 236 patients (0.30%) in the non-GLP-1 cohort. The hazard ratio comparing the two groups was 0.97 (95% CI: 0.81–1.16) with a p-value of 0.04 .

Conclusion:
In this large retrospective cohort, the incidence of ileus was low and comparable between obese hospitalized patients treated with GLP-1 RAs and those without GLP-1 exposure. Although uncommon in both groups, these findings underscore the need for prospective studies to further characterize the gastrointestinal effects of GLP-1 therapy in the inpatient setting.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*